{"name":"Hemab ApS","slug":"hemab-aps","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPN2pwMWdNV1MzbTNMZW9tQnlQRUhQQ2RHY2hHN1NEaWV3Tl9aT0FKcFA5R0FVT1Y1VVk3dkV3N3dlemJ5MTBvTFlMaFBvNTUxSVk4UDBKSE55M0sxUEJZWHRFN3pnMnp0WG41SWlLbXNGbS10WW1WR1EwWjNMd1k1SkRsY1RTZFhFN1BZSTJxVGZKS0J1b3dLdGRva0RKNENPVmx3eTM0Sm83MlFNa3dvb3BPSlNsTFFoeUlKMHZfalpNaVNkbTZsOXVMM3doejV4WHhJMzV3TU04M2NiNkVpdk5mU0hNdzd4WVVYWE9sc0hhZDJf?oc=5","date":"2026-03-05","type":"regulatory","source":"PR Newswire","summary":"Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia - PR Newswire","headline":"Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQR0JhSkJ5UzE2dmpBOC15RU9BR0taR0lpWk1FQXNwRzhIaXN0ZWFWOUNiQTJOcmtRNjB0ZmFlM09zcEJHTVBOSGpDS2pWcGZRVlJweUNwMjVvcmxlLUt4VFVqSHo1YTVQbUJ3WldzUTZwUmt3WWhSS01VbjFJWUdRcXByR3VLSE9FeTZQUjJYYWpKcFhlcU1lTjNjTWdrODdoX3JESUYzQ0d3ZnVlWGI3d3cta2o1SHNNLS1lQ05Vcks4TUZmeVpnWXFPWFZrTVlub2tWb2dYLV8wWjlpRkZWR0d5NlYyWndhN21KUUd3bS1MTlFNaVVfbUtNaHpaM19abGpuRHRFYzN5LWt2OF9BVFJ6ZFBaa1k?oc=5","date":"2025-10-27","type":"regulatory","source":"PR Newswire","summary":"Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders - PR Newswire","headline":"Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxORlcybjZfdzNsNGQzZExWWURLUHhSYXhkSFZHN1VJNUYxWWljQXNSMkJiWUFhRTh4bVBUeFM0ejNnZzREZkM2cC1HX0VYYUx6cEtFZ2dwRU5ram45R21TWGhHN2tuUmdVelNBenZSLWJxNWpQeF9SM3dZcmpJREJQZ1ZfUzQ1bDM1Zzdsa1I0U19rS2Q0Vnhha1BOOUpCS0s2QVViSHB6Y1NSdUx2NFJQQndoLUJ0akdiWGM4ODh5N0g?oc=5","date":"2025-10-27","type":"regulatory","source":"Fierce Biotech","summary":"Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions - Fierce Biotech","headline":"Hemab, working to build 'ultimate clotting company,' raises $157M series C for bleeding disorder ambitions","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-02-07","type":"regulatory","source":"PR Newswire","summary":"Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in Glanzmann Thrombasthenia and Preclinical Data from HMB-002 in Von Willebrand Dise","headline":"Hemab Therapeutics Presents Interim Data from Ongoing Phase 2 Study of HMB-001 as First Ever Prophylactic Treatment in G","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOS1YwalYwMEdsdFVyOGpUZHdYS3VnTGw1c0xmRVhBbkJ6SFFObWx0OF9pY3E4MWVBdnZtWUZ2a1F2NmZhSnJDaWFSN0FYVHN5ME5xdUs1OUMwMHRjR3VCVEc1NTdfUk9GaE1ZZVVXVElGUDFlMnRCTnNqRHFyWENYYg?oc=5","date":"2024-07-17","type":"regulatory","source":"European Biotechnology Magazine","summary":"Novo Holdings creates Hemab - European Biotechnology Magazine","headline":"Novo Holdings creates Hemab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE11VWJNTHJiSXNuQ1Fmd1BFNnZXcWhac09JVmRxLVZtXy1tamQyRmNGWUR3WTZuMUtsQk1XV1dUd2xPNU5RSl9vbEsxNEdBUVZaYzZpc21pOFdxalRWU09XTnNNZ2s5N1UyaEFtVWtGZw?oc=5","date":"2024-07-12","type":"pipeline","source":"medwatch.com","summary":"Life science companies are preparing for potential IPOs - medwatch.com","headline":"Life science companies are preparing for potential IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOUmtDUnVaWG12VEVyNERyRVR1RDRkRkhVSEdvYU1IaGhfOTBIdVFjTVdUTGFFT0wwc01oMjUtc3ZTbzFKZndKb3owN0V6a21hS1puZW02U2VqZG40MENjR2w4LVE0V0lyem0tMXdOY1JKSl8wQ3NaVkFMOVdVT0FiTkFlbVdxRk9aVDlCLUpPUUppMldPQjMzMV9TMkFEaDRqdFZHVlFFN1BiNmxUQlE1ZlF5YjlfT3FRZWhZbEJlM2ZhWnlZbkptVVNiOHFTUlNWRDMtY1FCU2hqbS1Vb3Y0VHlnQ1NCb2hPdzNUUFhjdHR2YjA3dXhYWDVVcjFOX1ZGSXZ5MGVER2pqRnp6UjNPSlFxYlRxOENlMHc?oc=5","date":"2023-06-24","type":"regulatory","source":"PR Newswire","summary":"Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency - PR Newswire","headline":"Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFByT2xDdWN5b3RXWXU1RWZPMjlMWFE4ZTh2aG1ZTGhPdEtpcFJUdnlZS3UwY1dwMENtX1ZiNGNOT0gtSUpuV3JOeWtfSVlfR0cyNS1PX0h1a1dTMUZLbnQwSFo4YjlhQVRId05PRUtfaw?oc=5","date":"2023-03-01","type":"regulatory","source":"medwatch.com","summary":"Hemab co-founder to start over in cancer company - medwatch.com","headline":"Hemab co-founder to start over in cancer company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOZVJrZUJIMDZLNkZORm9pUFpXRHppQnBsR205UDZUV2R6ckJmd2VfQ0NUbkt1bU9nWlY0akpFUEZEMWZ2Qm5ZRDg3UW5lWWJldnhSVms5R0RkR1JLenVldnVObkV3QUgwdzFQLWVEZXBWUlFuRjdlY0NiQ0d1WmIyVERuZkFMOW9yYUJ2UHNTNzRuNkU0RzlCZTgzNS03djZtbHN0enZMV2dWM2xwZW5pWWV3eW5kVmx1OGN0Zm9qWGhVVmMyYzNhaEJUNDMxT3VVeHhUZ3U3dWNwME5WaEFDeTBvV1U5VVV5c0ZleHhjUGhWS1dDWUtKUGI3Z2lPUVNTNWIxMEZydng3OFFfdjJVMW5mMnByaUVCQ2ZrZnRDZWg2ZlA4U3c?oc=5","date":"2023-02-21","type":"regulatory","source":"PR Newswire","summary":"Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders - PR Newswire","headline":"Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}